Published 18 hours ago • loading... • Updated 18 hours ago

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

Yesterday, Innovent Biologics announced that in the Phase 3 CLEAR-2 trial, 566 participants treated through Week 32 showed 89.3% and 90.1% PASI 90 maintenance at Week 56 with picankibart 100 mg and 200 mg.
PECONDLE, as China’s first IL-23p19 biologic, received NMPA market approval, and the CLEAR-2 randomized withdrawal and retreatment design examined maintenance necessity and post-withdrawal durability.
All key secondary endpoints were met with higher PASI 75, PASI 100, sPGA, and DLQI scores at Week 56, showing picankibart’s favorable safety profile and no new safety signals.
Maintenance treatment significantly reduced the risk of losing PASI 90 response, and nearly 51.7% of withdrawn participants still maintained PASI 90 after 24 weeks off treatment.
With over 7 million patients in China with psoriasis, Innovent’s pipeline and market presence position the company to support indication expansion and lifecycle management plans.

Insights by Ground AI